<DOC>
	<DOC>NCT01221259</DOC>
	<brief_summary>This study is designed as a single ascending dose study in healthy subjects to evaluate safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) in plasma and Cerebrospinal (CSF) following single oral doses of E2212.</brief_summary>
	<brief_title>A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1. Healthy men and women of nonchild bearing potential age 18 and 55 years old at the time of Screening; 2. Body mass index (BMI) 18 and 30 kg/m2 at Screening; 3. Are willing and able to comply with all aspects of the protocol; and 4. Provide written informed consent. 1. Clinically important abnormalities on physical examination, vital signs or clinical laboratories. 2. History of serious medical illness 3. Smoking or use of tobaccocontaining products within past 3 months 4. History of alcohol or drug abuse within past 2 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>